Det fremstilles af en celle, som har modtaget et gen (DNA), der sætter det i stand til at producere human koagulationsfaktor IX.
BeneFIX has been studied in previously treated patients with moderate or severe haemophilia B, as a prevention treatment (prophylaxis), or during and after surgery.